X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (211) 211
humans (165) 165
index medicus (159) 159
female (122) 122
middle aged (112) 112
male (104) 104
adult (102) 102
aged (100) 100
mutation (69) 69
cancer (64) 64
treatment outcome (61) 61
aged, 80 and over (60) 60
young adult (45) 45
neoplasms - drug therapy (43) 43
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
neoplasms - genetics (37) 37
clinical trials (36) 36
antineoplastic agents - therapeutic use (35) 35
prognosis (34) 34
article (33) 33
solid tumors (33) 33
adolescent (31) 31
chemotherapy (31) 31
care and treatment (29) 29
tumors (29) 29
molecular targeted therapy (28) 28
research (27) 27
disease-free survival (26) 26
patients (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
medicine & public health (25) 25
protein kinase inhibitors - therapeutic use (25) 25
neoplasms - pathology (24) 24
retrospective studies (24) 24
therapy (24) 24
phosphatidylinositol 3-kinases - genetics (23) 23
pharmacology/toxicology (22) 22
bevacizumab (21) 21
proto-oncogene proteins b-raf - genetics (21) 21
survival (21) 21
tor serine-threonine kinases - antagonists & inhibitors (19) 19
class i phosphatidylinositol 3-kinases (18) 18
metastasis (18) 18
neoplasms (18) 18
pharmacology & pharmacy (18) 18
targeted therapy (18) 18
antineoplastic combined chemotherapy protocols - administration & dosage (17) 17
breast-cancer (17) 17
cell lung-cancer (17) 17
colorectal-cancer (17) 17
dose-response relationship, drug (17) 17
research paper (17) 17
kaplan-meier estimate (16) 16
neoplasms - mortality (16) 16
pi3k (16) 16
cancer therapies (15) 15
clinical trials, phase i as topic (15) 15
drug therapy (15) 15
genetic aspects (15) 15
lung-cancer (15) 15
melanoma (15) 15
mutations (15) 15
neoplasm staging (15) 15
analysis (14) 14
breast neoplasms - drug therapy (14) 14
cell biology (14) 14
health aspects (14) 14
inhibition (14) 14
maximum tolerated dose (14) 14
metastatic breast-cancer (14) 14
studies (14) 14
resistance (13) 13
antimitotic agents (12) 12
antineoplastic agents (12) 12
biomarkers, tumor - genetics (12) 12
braf (12) 12
breast neoplasms - genetics (12) 12
cancer research (12) 12
colorectal cancer (12) 12
dosage and administration (12) 12
drug administration schedule (12) 12
expression (12) 12
inhibitors (12) 12
neoplasm metastasis (12) 12
phase i (12) 12
phase i trial (12) 12
phase-i (12) 12
survival analysis (12) 12
survival rate (12) 12
tor serine-threonine kinases - metabolism (12) 12
toxicity (12) 12
acquired-resistance (11) 11
animals (11) 11
breast cancer (11) 11
cancer patients (11) 11
cell-free dna (11) 11
complications and side effects (11) 11
high-throughput nucleotide sequencing (11) 11
neoplasms - metabolism (11) 11
proto-oncogene proteins - genetics (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Discovery, ISSN 2159-8274, 04/2018, Volume 8, Issue 4, pp. 389 - 391
Colorectal cancer with BRAF(V600E) mutation can be effectively treated with combination approaches involving inhibition of BRAF, MEK, and EGFR proteins.... 
DOSE-ESCALATION | CETUXIMAB | INHIBITION | PLASMA | ONCOLOGY | PHASE IB | MUTATION | CELL-FREE DNA | VEMURAFENIB | Colorectal Neoplasms | MAP Kinase Signaling System - drug effects | Mutation | Proto-Oncogene Proteins B-raf - genetics | Humans | ErbB Receptors - genetics | Index Medicus
Journal Article
Cell Cycle, ISSN 1538-4101, 06/2013, Volume 12, Issue 12, pp. 1817 - 1818
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2010, Volume 7, Issue 7, pp. 401 - 414
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, pp. e115383 - e115383
Background: Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing... 
MORTALITY | INTRAHEPATIC CHOLANGIOCARCINOMA | MULTIDISCIPLINARY SCIENCES | ERBB2 | GALLBLADDER CANCER | FREQUENT MUTATION | IDENTIFICATION | EXPRESSION | TRENDS | BAP1 | EPIDEMIOLOGY | Multivariate Analysis | Demography | Prognosis | Humans | Middle Aged | Male | Molecular Targeted Therapy | Tumor Suppressor Protein p53 - genetics | Young Adult | DNA Mutational Analysis | Receptors, Fibroblast Growth Factor - genetics | Aged, 80 and over | Adult | Female | Genes, Neoplasm - genetics | Bile Ducts, Intrahepatic - pathology | Cholangiocarcinoma - therapy | Treatment Outcome | Signal Transduction - genetics | Mutation - genetics | Genome, Human - genetics | Disease-Free Survival | Regression Analysis | Cholangiocarcinoma - pathology | Oncogene Proteins, Fusion - genetics | Cholangiocarcinoma - genetics | Aged | Genetic aspects | Tumor proteins | Health aspects | Cancer | TOR protein | Chromatin | Dehydrogenases | Profiling | Identification methods | Exons | p53 Protein | Genes | Lung cancer | Clinical trials | Medical records | Raf protein | Cancer therapies | DNA repair | Smad4 protein | Subgroups | Cdc4 protein | K-Ras protein | Metastases | Gene sequencing | Liver cancer | Gallbladder | Cholangiocarcinoma | Deoxyribonucleic acid--DNA | Medical research | Epidermal growth factor receptors | Review boards | Introns | MEK inhibitors | MAP kinase | Patients | ErbB-2 protein | Mcl-1 protein | Gene amplification | Chemotherapy | Medical prognosis | Mutation | Aberration | Fibroblast growth factor receptors | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 11/2014, Volume 6, Issue 6, pp. 306 - 306
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2016, Volume 22, Issue 22, pp. 5400 - 5402
In cancer, plasma-derived cell-free DNA can be used for detection of oncogenic aberrations relevant for treatment selection. A cell-free DNA-based test for... 
PLASMA | ONCOLOGY | TUMORS | CELL-FREE DNA | Biomarkers, Tumor - blood | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - genetics | DNA, Neoplasm - blood | Humans | DNA Copy Number Variations - genetics | Lung Neoplasms - blood | Mutation - genetics | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 7, pp. e22769 - e22769
Background: Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and... 
CELL LUNG-CANCER | KRAS MUTATIONS | COLON-CANCER | MELANOMA | EFFICACY | GENE | THYROID-CANCER | MULTIDISCIPLINARY SCIENCES | INHIBITOR | METASTATIC COLORECTAL-CANCER | ACTIVATING MUTATIONS | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Humans | Middle Aged | Male | Proto-Oncogene Proteins - genetics | Mutation - genetics | Phosphatidylinositol 3-Kinases - genetics | Young Adult | Class I Phosphatidylinositol 3-Kinases | Neoplasms - genetics | DNA Mutational Analysis | Proto-Oncogene Proteins B-raf - genetics | Adolescent | Polymerase Chain Reaction | Aged, 80 and over | Adult | Female | Aged | DNA, Neoplasm - genetics | Neoplasms - pathology | Genes, ras - genetics | Care and treatment | Cancer patients | Gene mutations | Analysis | Melanoma | Colorectal cancer | Genetic aspects | Nucleotide sequencing | Health aspects | Cancer | DNA sequencing | TOR protein | Laboratories | Colorectal carcinoma | Clinical trials | Raf protein | AKT protein | Metastasis | Kinases | Tissues | K-Ras protein | Gene sequencing | Pathways | Tumorigenesis | Pancreas | Deoxyribonucleic acid--DNA | Histology | Cervix | Patients | 1-Phosphatidylinositol 3-kinase | Polymerase chain reaction | Studies | Thyroid cancer | Biopsy | Medical prognosis | Mutation | Uterine cancer | Tumors | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2018, Volume 17, Issue 7, pp. 1595 - 1601
The European Society for Medical Oncology defines rare cancers as 5 or fewer cases per 100,000 persons per year. For many rare cancers, no standard of care... 
CELL LUNG-CANCER | TARGETED THERAPY | DABRAFENIB | MULTICENTER | GENOMICS | ONCOLOGY | LANDSCAPE | TRAMETINIB | OPEN-LABEL | Medical research | Therapy | Adenoid | Profiling | p53 Protein | Medical services | Clinical trials | Disease control | Patients | AACR | Alterations | Mutation | Cholangiocarcinoma | Tumors | Cancer | Rare cancers | Precision Oncology | Targeted therapy | Phase I trials
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4032 - 4038
Journal Article
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 10, pp. 3012 - 3022
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has... 
Hepatocellular carcinoma | AKT | PI3K | Next generation sequencing | MTOR | Index Medicus
Journal Article